2 Tower Place, Suite 940
South San Francisco
About Verge Genomics
Currently, it takes 12 years and $2.6 billion to get a single drug to market, with the drug discovery and development process costing $1.4 billion. At Verge Genomics, we believe there is a better way: we aim to improve the traditional drug discovery process with approaches based on systems biology, machine learning on human patient data, and drug screening in human cell cultures.
Founded in 2015 by CEO Alice Zhang, we’ve raised $32 million in Series A financing to build a next-generation biopharmaceutical company focused on accelerating development of life-saving treatments for patients with neurodegenerative diseases, including ALS, Parkinson’s Disease, and Alzheimer’s Disease.
As an emerging startup, Verge Genomics provides growth opportunities into other areas of the company. Being one of the early employees at Verge, your work will have a direct impact on the foundation of a groundbreaking new drug development model. You will be empowered to own your work and makes real decisions. In addition to competitive compensation and benefits, we offer perks like unlimited vacation/sick days, and free lunch delivered every day.
+ Patient Driven - Inspired and driven by the people who need us
+ Team of Founders - We are each responsible for the success of the company and each other
+ Transparency - Express ourselves with candor
+ Growth Mindset - Always seeking opportunities to improve
+ Grit - Persevere in the face of adversity
Alice Zhang Is Using AI To Transform Drug Discovery - 30 Under 30 - Forbes. Alice Zhang’s startup, Verge Genomics, thinks merging the latest in computer science with new technologies for decoding the human genome can improve the success rate for new drug discovery. Verge is focused on Alzheimer’s and Parkinson’s, areas that most drug companies have abandoned as hopeless.
9 articles with Verge Genomics
Verge Genomics, a biotech company that has created an industry leading all-in-human, artificial-intelligence-powered drug discovery and development platform focused on therapies for serious genetic diseases, announced today that Andrew Allen, M.D., Ph.D., President and Chief Executive Officer at Gritstone bio, has been appointed as an Independent Director to its Board of Directors.
Verge Genomics Announces Three-Year Collaboration With Lilly to Discover and Develop Novel Treatments Using Its AI-Driven All-in-Human Platform
Verge Genomics, a biotech company that has created an industry leading all-in-human, artificial-intelligence-powered drug discovery and development platform focused on therapies for serious genetic diseases, announced a three-year collaboration with Eli Lilly and Company to research and develop novel therapies for the treatment of amyotrophic lateral sclerosis, a devastating motor neuron disease.
Startups have passion and big, bold ideas. Pharma has the funds and human resources. Together, they can change the future of medicine.
Verge Genomics Presents Preclinical Data Supporting Broad-Spectrum Potential of Its Novel, Oral Antiviral at the 31st European Congress of Clinical Microbiology & Infectious Diseases
Verge Genomics today announced that data from preclinical studies using its novel PIKfyve inhibitor VRG101 showed broad spectrum of antiviral activity. The results will be presented at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) online meeting being held July 9-12, 2021.
Verge Genomics Announces the Addition of Mario Saltarelli, M.D., Ph.D., to its Scientific Advisory Board
Verge Genomics, a drug discovery company developing therapies for neurological diseases by integrating a unique all-in-human genomic platform with machine learning, announced today that Mario Saltarelli, M.D., Ph.D., CEO of U.S. Green Valley Pharmaceuticals, has been appointed to Verge’s Scientific Advisory Board.
5/7/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
A recent report by Deerfield Management Company revealed an unsettling but unsurprising truth: There is a significant gender gap on the boards of venture-backed healthcare companies.
Verge Genomics, a drug discovery company developing therapies for neurological diseases by integrating a unique all-in-human genomic platform with machine learning, announced today that Steve Kanes, M.D., Ph.D., Chief Medical Officer at Sage Therapeutics, a leader in developing therapies that support brain health, has been appointed to its board of directors.
Verge Genomics, a drug discovery company that uses artificial intelligence and machine learning to develop new therapeutics, secured $32 million in a Series A financing round to accelerate its drug discovery programs.